Janssen Pharma to collaborate with Sanofi in Janssen's extraintestinal pathogenic Escherichia coli vaccine programme
Janssen Pharmaceuticals, Inc. a Johnson & Johnson Company, announced a development and commercialization agreement with Sanofi for Janssen’s extraintestinal pathogenic Escherichia coli (ExPEC) investigational vaccine program
The lead vaccine candidate is currently being evaluated in the Phase III Embrace study for the prevention of invasive E. coli disease (IED) in adults aged 60 years and older.IED occurs when bacteria that normally reside in the intestines leave the intestinal tract and infect other parts of the body. This can result in a range of infections that can be serious and life-threatening for adults over 60, including bacteremia (blood infections) and sepsis. ExPEC is a leading bacterial cause of sepsis.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins